^
    2d
    Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion). (PubMed, Lung Cancer)
    Although the primary endpoint was not met, the combination provided durable control of MPE and was well tolerated, suggesting potential value in symptom-focused management of this high-risk subgroup.
    P2 data • Journal • Pleural effusion
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    erlotinib • Cyramza (ramucirumab)
    3d
    Paradoxical Pyogenic Granuloma Associated With Ramucirumab but Not Bevacizumab: A Case Suggesting Differential Effects of VEGF Receptor and Ligand Inhibition. (PubMed, Respirol Case Rep)
    We describe a 75-year-old man with advanced lung adenocarcinoma who developed multiple bleeding pyogenic granulomas during docetaxel plus ramucirumab therapy. This intra-patient contrast suggests that VEGFR-2 blockade and VEGF ligand inhibition may have different effects on paradoxical vascular proliferative lesions. Clinicians should recognize this rare toxicity and consider switching anti-angiogenic strategy in selected cases.
    Journal
    |
    KDR (Kinase insert domain receptor)
    |
    Avastin (bevacizumab) • docetaxel • Cyramza (ramucirumab)
    3d
    D6187C00001: A trial to learn how safe different combinations of anti-cancer drugs are and how well they work in adults with advanced or metastatic non-small cell lung cancer (NSCLC) (2025-524843-11-00)
    P1/2, N=20, Not yet recruiting, AstraZeneca AB
    New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement
    |
    Cyramza (ramucirumab) • rilvegostomig (AZD2936)
    6d
    Therapeutic Targeting of VEGFR-2, PD-L1, and EGFR-MET Pathways in Non-Small Cell Lung Cancer: Clinical Progress with Ramucirumab, Atezolizumab, and Amivantamab. (PubMed, J Clin Med)
    Ramucirumab, a monoclonal antibody targeting vascular endothelial growth factor receptor-2 (VEGFR-2), has shown a survival benefit when combined with docetaxel in patients with previously treated advanced NSCLC. Collectively, these agents highlight the expanding role of antibody-based therapies in NSCLC and underscore the importance of biomarker-driven patient selection and treatment personalization. Ongoing research into resistance mechanisms, predictive biomarkers, and combination approaches is expected to further refine the integration of antibody-based strategies in precision oncology for NSCLC.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KDR (Kinase insert domain receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tecentriq (atezolizumab) • docetaxel • Cyramza (ramucirumab)
    8d
    Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=43, Completed, Washington University School of Medicine | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Cyramza (ramucirumab)
    10d
    CLARITY-Gastric 01: AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (clinicaltrials.gov)
    P3, N=572, Recruiting, AstraZeneca | Active, not recruiting --> Recruiting
    Enrollment open
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression • CLDN18.2 positive • CLDN1 positive
    |
    paclitaxel • docetaxel • AiTan (rivoceranib) • Cyramza (ramucirumab) • irinotecan • Lonsurf (trifluridine/tipiracil) • sonesitatug vedotin (AZD0901)
    10d
    ALTAIR: A Platform Study in Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1/2, N=152, Recruiting, AstraZeneca | N=56 --> 152
    Enrollment change • Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • Cyramza (ramucirumab) • pemetrexed • rilvegostomig (AZD2936)
    16d
    Case Report: Durable complete response to olaparib in a patient with BRCA2-driven metastatic gastric adenocarcinoma after failure of chemo-immunotherapy. (PubMed, Front Oncol)
    The disease progressed following platinum-based chemotherapy combined with nivolumab and subsequent paclitaxel-ramucirumab therapy. The patient achieved a complete metabolic response on FDG PET-CT, which has been sustained for more than three years under continuous olaparib therapy with acceptable tolerability. This case highlights the importance of molecularly guided treatment strategies and homologous recombination repair deficiency in selected patients with advanced gastric cancer.
    Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    BRCA2 mutation
    |
    Tempus xT Assay
    |
    Opdivo (nivolumab) • Lynparza (olaparib) • paclitaxel • Cyramza (ramucirumab)
    16d
    Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Gilead Sciences
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    PD-L1 expression • HER-2 negative
    |
    Opdivo (nivolumab) • paclitaxel • Cyramza (ramucirumab) • denikitug (GS-1811)
    17d
    A Study on the Efficacy and Safety of Sintilimab Combined with Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients with Short-term Recurrence after Adjuvant Therapy (ChiCTR2600119362)
    P2, N=30, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    paclitaxel • Tyvyt (sintilimab) • Cyramza (ramucirumab)
    17d
    2138-CL-0101: A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer (clinicaltrials.gov)
    P1, N=398, Recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: May 2027 --> May 2028 | Trial primary completion date: Nov 2026 --> May 2028
    Trial completion date • Trial primary completion date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CA 19-9 (Cancer antigen 19-9)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • paclitaxel • 5-fluorouracil • capecitabine • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • ASP2138
    19d
    Mutation-Specific Response to Ramucirumab in EGFR-Mutated Metastatic NSCLC: Insights From Circulating Cell-Free DNA Profiling (Liquid Biopsy Japan Addendum of RELAY Phase 3 Randomized Study). (PubMed, JTO Clin Res Rep)
    A previous analysis of the RELAY phase 3 liquid biopsy addendum demonstrated suppressed EGFR-activating mutation allele count, increased total cell-free DNA (cfDNA) concentration, and shortened cfDNA fragment size with ramucirumab (RAM) plus erlotinib (ERL) versus placebo (PL) plus ERL in patients with EGFR-mutated NSCLC. This updated analysis revealed differences in total cfDNA concentration and T790M mutation rates between ex19del and L858R. RAM plus ERL may exhibit greater antitumor effects on L858R, supporting the favorable survival benefits observed previously in patients with a L858R.
    P3 data • Journal • Liquid biopsy
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    erlotinib • Cyramza (ramucirumab)